These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2523194)

  • 21. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment.
    Kobayashi S; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Ohye H; Suzuki M; Yoshihara A; Iwaku K; Sugino K; Ito K
    Thyroid; 2014 May; 24(5):796-801. PubMed ID: 24341564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SIDE EFFECTS OF PTU AND MMI IN THE TREATMENT OF HYPERTHYROIDISM: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Yu W; Wu N; Li L; Wang J; OuYang H; Shen H
    Endocr Pract; 2020 Feb; 26(2):207-217. PubMed ID: 31652102
    [No Abstract]   [Full Text] [Related]  

  • 23. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.
    Gianetti E; Russo L; Orlandi F; Chiovato L; Giusti M; Benvenga S; Moleti M; Vermiglio F; Macchia PE; Vitale M; Regalbuto C; Centanni M; Martino E; Vitti P; Tonacchera M
    J Endocrinol Invest; 2015 Sep; 38(9):977-85. PubMed ID: 25840794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The occurrence of agranulocytosis due to antithyroid drugs in a cohort of patients with Graves disease treated with radioactive iodine 131I during 14 years].
    Cepková J; Gabalec F; Svilias I; Horáček J
    Vnitr Lek; 2014 Oct; 60(10):832-6. PubMed ID: 25382005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of agranulocytosis and anti-neutrophil cytoplasmic antibody-associated vasculitis caused by two antithyroid drugs: A pharmacovigilance study using the WHO international database.
    Han JY; Lee JM; Jung SY; Kim MS; Lee SW; Kronbichler A; Tizaoui K; Koyanagi A; Kim EY; Song K; Chae HW; Yon DK; Shin JI; Smith L
    Fundam Clin Pharmacol; 2024 Aug; 38(4):780-788. PubMed ID: 38342499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety of methimazole and propylthiouracil in pregnancy: a systematic review.
    Hackmon R; Blichowski M; Koren G
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1077-1086. PubMed ID: 23231846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatotoxicity and cutaneous reactions after antithyroid drug administration.
    Otsuka F; Noh JY; Chino T; Shimizu T; Mukasa K; Ito K; Ito K; Taniyama M
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):310-5. PubMed ID: 22332800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hyperthyroidism with a small single daily dose of methimazole.
    Shiroozu A; Okamura K; Ikenoue H; Sato K; Nakashima T; Yoshinari M; Fujishima M; Yoshizumi T
    J Clin Endocrinol Metab; 1986 Jul; 63(1):125-8. PubMed ID: 3011835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse effects related to antithyroid drugs and their dose regimen.
    Romaldini JH; Werner MC; Bromberg N; Werner RS
    Exp Clin Endocrinol; 1991 May; 97(2-3):261-4. PubMed ID: 1915643
    [No Abstract]   [Full Text] [Related]  

  • 30. A Disproportionality Analysis of the Adverse Effect Profiles of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Using the Japanese Adverse Drug Event Report Database.
    Arai M; Tsuno T; Konishi H; Nishiyama K; Terauchi Y; Inoue R; Shirakawa J
    Thyroid; 2023 Jul; 33(7):804-816. PubMed ID: 37130038
    [No Abstract]   [Full Text] [Related]  

  • 31. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves' disease.
    Kubota S; Ohye H; Yano G; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Kuma K; Miyauchi A
    Endocr J; 2006 Oct; 53(5):603-7. PubMed ID: 16896267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study.
    Andersen SL; Olsen J; Wu CS; Laurberg P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4373-81. PubMed ID: 24151287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
    Reinwein D; Benker G; Lazarus JH; Alexander WD
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents.
    Abuid J; Larsen PR
    J Clin Invest; 1974 Jul; 54(1):201-8. PubMed ID: 4134836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
    Huang CN; Hsu TC; Chou HH; Tsay GJ
    J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease.
    Tamai H; Takaichi Y; Morita T; Komaki G; Matsubayashi S; Kuma K; Walter RM; Kumagai LF; Nagataki S
    Clin Endocrinol (Oxf); 1989 May; 30(5):525-30. PubMed ID: 2605789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Desensitization to Methimazole.
    Mazhari A; Emanuele MA; Espiritu B
    Endocr Pract; 2021 Mar; 27(3):185-190. PubMed ID: 33779553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan.
    Suzuki N; Noh JY; Hiruma M; Kawaguchi A; Morisaki M; Ohye H; Suzuki M; Matsumoto M; Kunii Y; Iwaku K; Yoshihara A; Watanabe N; Sugino K; Ito K
    Thyroid; 2019 Oct; 29(10):1390-1398. PubMed ID: 31573408
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease.
    Sera N; Ashizawa K; Ando T; Abe Y; Ide A; Usa T; Tominaga T; Ejima E; Yokoyama N; Eguchi K
    Thyroid; 2000 Jul; 10(7):595-9. PubMed ID: 10958312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.